Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,995 | -3,143 | -17,054 | -36,065 | -66,727 |
| Depreciation Amortization | 245 | 632 | 1,068 | 1,236 | 1,380 |
| Accounts receivable | 2,718 | -2,718 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -2,633 | -353 | 2,679 | 1,641 | -320 |
| Other Working Capital | 520 | -2,356 | 844 | -118 | -1,035 |
| Other Operating Activity | -1,182 | 3,223 | -1,878 | 1,461 | 31,701 |
| Operating Cash Flow | $-6,327 | $-4,715 | $-14,341 | $-31,845 | $-35,001 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 1 | 38 | 309 | -66 | -89 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 2,145 |
| Investing Cash Flow | $1 | $38 | $309 | $-66 | $2,056 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 8,812 | 2,918 |
| Debt Issued | 2,865 | 3,668 | N/A | N/A | 11,874 |
| Debt Repayment | -1,255 | -610 | -9,401 | N/A | -11,383 |
| Common Stock Issued | 9,691 | N/A | 4,888 | N/A | 47,741 |
| Other Financing Activity | -300 | 381 | 431 | 0 | -362 |
| Financing Cash Flow | $11,001 | $3,439 | $-4,082 | $8,812 | $50,788 |
| Beginning Cash Position | 116 | 1,354 | 19,468 | 42,567 | 24,724 |
| End Cash Position | 4,791 | 116 | 1,354 | 19,468 | 42,567 |
| Net Cash Flow | $4,675 | $-1,238 | $-18,114 | $-23,099 | $17,843 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,327 | -4,715 | -14,341 | -31,845 | -35,001 |
| Capital Expenditure | N/A | N/A | N/A | -66 | -89 |
| Free Cash Flow | -6,327 | -4,715 | -14,341 | -31,911 | -35,090 |